Therapeutic evolution: translating pharmacological innovation in tangible benefit for people with hemophilia A. A multistakeholder perspective

The advances that have marked the history of hemophilia represent a concrete example of therapeutic evolution.The progress made over the years has been able to revolutionize its treatment, bringing about a radical changeboth in the therapeutic algorithm and in life expectancy. Considering the recent milestones achieved, it would beanachronistic to maintain the same therapeutic goals as in the past; the normalization of hemostasis is the pathleading to the ultimate therapeutic goal, which should be the achievement of health equity: a life comparable tothat of a person without such a condition.This article highlights the need for a multidisciplinary approach to the management of hemophilia, as raisedfrom the different perspectives of the stakeholders who contributed: pharmacologists, patients, clinicians,bioethicists, pain therapists, and pharmacoeconomists. This has made it possible to gain a comprehensive viewthat reflects the complexity of managing a chronic disease such as hemophilia.